Cadrenal Therapeutics Clears FDA Hurdle for Phase 3 Trial of HIT Treatment — Cadrenal Therapeutics, Inc.

Event summary

Cadrenal Therapeutics received FDA guidance to advance CAD-1005 directly into a pivotal Phase 3 trial for heparin-induced thrombocytopenia (HIT).
Phase 2 data showed >25% absolute reduction in thrombotic events with CAD-1005 added to standard therapy.
Planned Phase 3 study will enroll ~120 patients across up to 50 global centers, targeting NDA submission in 2029.
CAD-1005 is the only treatment in development targeting the underlying immune mechanisms of HIT.

The big picture

Cadrenal Therapeutics is advancing the first new treatment for heparin-induced thrombocytopenia in over two decades, addressing a condition with mortality rates exceeding 20%. The FDA's guidance accelerates CAD-1005's path to market, potentially filling a critical gap in treating this immune-mediated thrombotic disorder. With Orphan Drug and Fast Track designations already secured, the company is positioning itself as a key player in specialized anticoagulant therapies.

What we're watching

Regulatory Pathway: Whether the FDA's guidance ensures a smooth path to NDA submission for CAD-1005 in 2029.
Clinical Execution: The pace at which Cadrenal can enroll and complete the Phase 3 trial across global centers.
Market Opportunity: How CAD-1005's unique mechanism could position it as a first-line therapy for HIT if approved.